NEW YORK (GenomeWeb News) – Consumer genomics firm Navigenics has cut the price of its comprehensive genetic screening service by 60 percent, from $2,500 to $999, the firm announced on its blog, The Navigator.

A thousand dollars buys customers a year subscription to Navigenics' Health Compass testing services, which includes genetic risk data for 28 diseases and conditions; an hour-long session with a genetic counselor; and updates to risk scores as new gene associations and diseases are added to the service.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.